Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Novavax Stock: Positioned for Further Rally

Stock MarketsSep 28, 2021 05:00PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. Novavax Stock: Positioned for Further Rally

The COVID-19 vaccine market in developed economies is dominated by the likes of Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA). These companies have benefitted from an early-mover advantage.

However, the vaccination drive is far from over. According to the global vaccine alliance (GAVI), 80% of the population in high- and upper-middle income countries have received at least one dose of the vaccine. That number is abysmal for low- and lower-middle-income countries. Only 20% of those populations has received at least one dose of the vaccine.

As the focus shifts to equitable distribution of the vaccine, Novavax (NASDAQ:NVAX) seems to be a prime beneficiary.

NVAX stock has already trended higher by 80.3% for year-to-date 2021. (See NVAX stock charts on TipRanks)

With vaccine deliveries around the corner, further stock upside seems likely. I am bullish on Novavax, with the company at a growth inflection point.

Focus on Low-Income Countries

Novavax is a leading contributor to the World Health Organization-backed COVAX initiative. The company has already committed 1.1 billion doses of its vaccine.

Last week, Novavax and the Serum Institute of India announced submission to the World Health Organization for emergency use listing of the vaccine. The company has also separately applied with authorities in India, Indonesia and the Philippines for emergency use approval.

It’s also worth noting that Novavax has advance purchase agreements for approximately 400 million doses of the vaccine. This agreement is with the European Union, Canada, Switzerland, Australia and the U.K. Recently, the company also signed an agreement with the government of Japan for 150 million doses of the vaccine.

The key point is that Novavax has an order pipeline from developed markets. Additionally, there is significant visibility for pipeline boost from low-income countries. This provides strong revenue and cash flow visibility for 2022.

Paving Way for Long-Term Growth

Novavax also seems to be positioning itself for long-term cash flows. There are two factors that are likely to play an important role.

First and foremost, a single booster dose has demonstrated four-fold increases in neutralizing antibody levels. With encouraging results, the booster dose is likely to provide scope for incremental revenue.

Furthermore, Novavax has already initiated Phase 1 and 2 clinical trials for a combination of the COVID-19 vaccine and seasonal influenza. Positive results on this front can be a possible source of long-term revenue from the vaccine.

It’s also worth noting that as of Q2 2021, Novavax reported cash and equivalents of $2.1 billion. It’s likely that the company’s cash position will swell further in 2022.

This is important as Novavax already has a deep pipeline of candidates in various stages of clinical trials. With strong financial flexibility, the company is positioned to pursue multiple vaccine candidates.

Currently, the company’s pipeline is for therapeutic areas that include seasonal influenza, respiratory syncytial virus, Ebola virus, Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome.

Wall Street’s Take

According to TipRanks’ analyst rating consensus, NVAX stock comes in as a Strong Buy, with three Buys assigned in the past three months.

The average NVAX price target is $290.33 per share, implying 43% upside potential from current levels.

Concluding Views

From a manufacturing and supply perspective, Novavax is well positioned. By Q4 2021, the company expects to ramp up manufacturing to 150 million doses per month.

Additionally, Novavax has a licensing agreement with the Serum Institute of India, SK bioscience, and Takeda. Therefore, the company is positioned to service the order backlog in 2022 and beyond.

Overall, NVAX stock is likely to trend higher once the company receives approval from the World Health Organization. A pending emergency use authorization approval with the United States is also a stock upside catalyst.

Disclosure: At the time of publication, Faisal Humayun did not have a position in any of the securities mentioned in this article.

Disclaimer: The information contained in this article represents the views and opinion of the writer only, and not the views or opinion of TipRanks or its affiliates, and should be considered for informational purposes only. TipRanks makes no warranties about the completeness, accuracy or reliability of such information. Nothing in this article should be taken as a recommendation or solicitation to purchase or sell securities. Nothing in the article constitutes legal, professional, investment and/or financial advice and/or takes into account the specific needs and/or requirements of an individual, nor does any information in the article constitute a comprehensive or complete statement of the matters or subject discussed therein. TipRanks and its affiliates disclaim all liability or responsibility with respect to the content of the article, and any action taken upon the information in the article is at your own and sole risk. The link to this article does not constitute an endorsement or recommendation by TipRanks or its affiliates. Past performance is not indicative of future results, prices or performance.

Novavax Stock: Positioned for Further Rally
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email